advanced breast cancer / CRC / NSCLC
Oncology · 2014–2014
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| capecitabine, megestrol, toremifene, vinorelbine Multiple indications across four drugs: capecitabine for advanced breast cancer, colorectal cancer, and oesophago-gastric cancer; megestrol for… | Nov 2014 | Recommended | no section in document |
What the PBS pays
$2M in government benefit over 2024–25, across 41,299 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| capecitabine, megestrol, toremifene, vinorelbine | $2.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.